Voyager Therapeutics (NASDAQ:VYGR) Stock Price Down 3.7%

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) shares traded down 3.7% during trading on Thursday . The company traded as low as $7.26 and last traded at $7.29. 90,007 shares changed hands during trading, a decline of 90% from the average session volume of 898,971 shares. The stock had previously closed at $7.57.

Wall Street Analysts Forecast Growth

VYGR has been the topic of several analyst reports. Citigroup began coverage on shares of Voyager Therapeutics in a report on Thursday, March 7th. They issued a "buy" rating and a $16.00 price objective on the stock. Wells Fargo & Company upgraded shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $9.00 to $14.00 in a report on Tuesday, January 2nd. HC Wainwright began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 target price on the stock. StockNews.com upgraded shares of Voyager Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, March 9th. Finally, Guggenheim began coverage on shares of Voyager Therapeutics in a report on Tuesday, March 26th. They issued a "buy" rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $19.33.

Voyager Therapeutics Price Performance

The firm has a market cap of $402.91 million, a P/E ratio of 2.40 and a beta of 0.96. The business's 50-day moving average is $8.81 and its two-hundred day moving average is $7.96.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. Equities research analysts predict that Voyager Therapeutics, Inc. will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VYGR. Armistice Capital LLC grew its position in Voyager Therapeutics by 15.3% in the third quarter. Armistice Capital LLC now owns 4,178,000 shares of the company's stock valued at $32,380,000 after purchasing an additional 554,000 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $1,569,000. Kestra Advisory Services LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $980,000. Massachusetts Financial Services Co. MA bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $887,000. Finally, Inspire Investing LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at about $641,000. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.